{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:13:18Z","timestamp":1786194798096,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40265-024-02004-9","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T07:01:57Z","timestamp":1709622117000},"page":"459-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Aponermin: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"2004_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104716","author":"H Dianat-Moghadam","year":"2020","unstructured":"Dianat-Moghadam H, Heidarifard M, Mahari A, et al. TRAIL in oncology: from recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacol Res. 2020. https:\/\/doi.org\/10.1016\/j.phrs.2020.104716.","journal-title":"Pharmacol Res"},{"issue":"10","key":"2004_CR2","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.3390\/cancers15102752","volume":"15","author":"JM Pimentel","year":"2023","unstructured":"Pimentel JM, Zhou JY, Wu GS. The role of TRAIL in apoptosis and immunosurveillance in cancer. Cancers (Basel). 2023;15(10):2752.","journal-title":"Cancers (Basel)."},{"key":"2004_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.pharmthera.2015.09.001","volume":"155","author":"GP Amarante-Mendes","year":"2015","unstructured":"Amarante-Mendes GP, Griffith TS. Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther. 2015;155:117\u201331.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"2004_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/sj.neo.7900203","volume":"3","author":"RK Srivastava","year":"2001","unstructured":"Srivastava RK. TRAIL\/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia. 2001;3(6):535\u201346.","journal-title":"Neoplasia"},{"issue":"4","key":"2004_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib6040016","volume":"6","author":"A Dubuisson","year":"2017","unstructured":"Dubuisson A, Micheau O. Antibodies and derivatives targeting DR4 and DR5 for cancer therapy. Antibodies (Basel). 2017;6(4):16.","journal-title":"Antibodies (Basel)."},{"issue":"3","key":"2004_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2004_CR7","unstructured":"World Health Organization. The Global Cancer Observatory (China). 2021. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/160-china-fact-sheets.pdf. Accessed 22 Jan 2024"},{"issue":"6","key":"2004_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","volume":"12","author":"S Kumar","year":"2022","unstructured":"Kumar S, Baizer L, Callander NS, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022;12(6):98.","journal-title":"Blood Cancer J"},{"issue":"8","key":"2004_CR9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"issue":"3","key":"2004_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1182\/blood.V98.3.795","volume":"98","author":"CS Mitsiades","year":"2001","unstructured":"Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL\/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001;98(3):795\u2013804.","journal-title":"Blood"},{"issue":"11","key":"2004_CR11","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1038\/sj.leu.2401501","volume":"13","author":"Y Gazitt","year":"1999","unstructured":"Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 1999;13(11):1817\u201324.","journal-title":"Leukemia"},{"issue":"6","key":"2004_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3892\/br.2016.650","volume":"4","author":"Y Jian","year":"2016","unstructured":"Jian Y, Chen Y, Geng C, et al. Target and resistance-related proteins of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on myeloma cell lines. Biomed Rep. 2016;4(6):723\u20137.","journal-title":"Biomed Rep."},{"issue":"2","key":"2004_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41418-022-01059-z","volume":"30","author":"A Montinaro","year":"2023","unstructured":"Montinaro A, Walczak H. Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries. Cell Death Differ. 2023;30(2):237\u201349.","journal-title":"Cell Death Differ"},{"key":"2004_CR14","unstructured":"\u6c99\u827e\u7279 (aponermin): Chinese prescribing infomation. Wuhan: Wuhan HITECK Biopharmaceutical Co., Ltd; 2023."},{"key":"2004_CR15","unstructured":"National Medical Products Administration. The state Food and Drug Administration approves the launch of aponermin for injection [media release]. https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20231102155258118.html?type=pc&m=. Accessed 2 Nov 2023."},{"issue":"11","key":"2004_CR16","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/j.1745-7254.2005.00206.x","volume":"26","author":"F Fang","year":"2005","unstructured":"Fang F, Wang AP, Yang SF. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol Sin. 2005;26(11):1373\u201381.","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"2004_CR17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1097\/COC.0000000000000404","volume":"41","author":"J Hou","year":"2018","unstructured":"Hou J, Qiu L, Zhao Y, et al. A phase1b dose escalation study of recombinant circularly permuted TRAIL in patients with relapsed or refractory multiple myeloma. Am J Clin Oncol. 2018;41(10):1008\u201314.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2004_CR18","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1186\/s12885-023-11489-8","volume":"23","author":"Z Xia","year":"2023","unstructured":"Xia Z, Leng Y, Fang B, et al. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial. BMC Cancer. 2023;23(1):980.","journal-title":"BMC Cancer"},{"key":"2004_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2016.12.010","volume":"389","author":"Y Wu","year":"2017","unstructured":"Wu Y, Giaisi M, K\u00f6hler R, et al. Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model. Cancer Lett. 2017;389:70\u20137.","journal-title":"Cancer Lett"},{"issue":"5","key":"2004_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/hon.3045","volume":"40","author":"Y Leng","year":"2022","unstructured":"Leng Y, Hu X, Li L, et al. Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells. Hematol Oncol. 2022;40(5):999\u20131008.","journal-title":"Hematol Oncol"},{"issue":"4","key":"2004_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2021.12556","volume":"21","author":"H Wang","year":"2021","unstructured":"Wang H, Geng C, Zhou H, et al. Cyclopamine sensitizes multiple myeloma cells to circularly permuted TRAIL-induced apoptosis. Oncol Lett. 2021;21(4):1\u20137.","journal-title":"Oncol Lett"},{"issue":"8","key":"2004_CR22","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3724\/abbs.2023160","volume":"55","author":"J Liu","year":"2023","unstructured":"Liu J, Zhu T, Liu J, et al. Synergistic antitumor effects of circularly permuted TRAIL with doxorubicin in triple-negative breast cancer. Acta Biochim Biophys Sin (Shanghai). 2023;55(8):1247\u201356.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"2004_CR23","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.12659\/MSM.909390","volume":"24","author":"T Sun","year":"2018","unstructured":"Sun T, Zhu T, Liang X, et al. Effects of recombinant circularly permuted tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) (Recombinant Mutant Human TRAIL) in combination with 5-fluorouracil in human colorectal cancer cell lines HCT116 and SW480. Med Sci Monit. 2018;24:2550\u201361.","journal-title":"Med Sci Monit"},{"issue":"8","key":"2004_CR24","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","volume":"111","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968\u201377.","journal-title":"Blood"},{"issue":"2","key":"2004_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/10428194.2022.2136950","volume":"64","author":"AS Rosenberg","year":"2023","unstructured":"Rosenberg AS. From mechanism to resistance - changes in the use of dexamethasone in the treatment of multiple myeloma. Leuk Lymphoma. 2023;64(2):283\u201391.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2004_CR26","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00280-017-3310-0","volume":"79","author":"Y Leng","year":"2017","unstructured":"Leng Y, Hou J, Jin J, et al. Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed\/refractory multiple myeloma: a phase 2 study. Cancer Chemother Pharmacol. 2017;79(6):1141\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"2004_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/ajh.23822","volume":"89","author":"C Geng","year":"2014","unstructured":"Geng C, Hou J, Zhao Y, et al. A multicenter, open-label phase II study of recombinant CPT (circularly permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. Am J Hematol. 2014;89(11):1037\u201342.","journal-title":"Am J Hematol"},{"issue":"21","key":"2004_CR28","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/blood.V124.21.3478.3478","volume":"124","author":"WM Chen","year":"2014","unstructured":"Chen WM, Wei P, Yang SF, et al. Transiently elevated AST\/LDH are associated with clinical response to recombinant circularly permuted TRAIL (CPT) plus thalidomide in patients with relapsed and\/or refractory multiple myeloma [abstract no. 3478]. Blood. 2014;124(21):3478.","journal-title":"Blood"},{"issue":"1","key":"2004_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40880-016-0140-0","volume":"35","author":"Y Leng","year":"2016","unstructured":"Leng Y, Qiu L, Hou J, et al. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma. Chin J Cancer. 2016;35(1):86.","journal-title":"Chin J Cancer"},{"issue":"Suppl. 1","key":"2004_CR30","first-page":"369","volume":"99","author":"P Wei","year":"2014","unstructured":"Wei P, Yang S, Zheng X, et al. Transient elevation of AST or LDH as an early pharmacodynamic biomarker of recombinant circularly permuted TRAIL (CPT) in treating patients with relapsed or refractory multiple myeloma [abstract no. P974]. Haematologica. 2014;99(Suppl. 1):369.","journal-title":"Haematologica"}],"updated-by":[{"DOI":"10.1007\/s40265-024-02025-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02004-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02004-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02004-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T03:39:08Z","timestamp":1716003548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02004-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2004"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02004-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-024-02025-4","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"5 March 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-024-02025-4","URL":"https:\/\/doi.org\/10.1007\/s40265-024-02025-4","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}